Strata Critical Medical Q3 2026 net loss from continuing operations narrows 21% year-over-year to $7.62 million; Q3 2026 revenue rises 50% year-over-year to $74.08 million
- Strata Critical Medical’s Q3 2026 net loss from continuing operations narrowed 21% year-over-year to $7.62 million.
- Revenue climbed 50% year-over-year to $74.08 million, driven by Clinical acquisitions, partially offset by Logistics.
- A new $20 million share repurchase authorization will be deployed alongside the acquisition strategy.
- Revenue guidance for 2026 remained at $285 million–$295 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Strata Critical Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030700PRIMZONEFULLFEED9868787) on November 03, 2026, and is solely responsible for the information contained therein.